Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- BAN2401 Gets FDA’s Breakthrough Therapy Tag: Eisai/Biogen
June 25, 2021
- Boehringer, Japan Cancer Foundation Join Hands for Oncology Research
June 24, 2021
- Shionogi President Earns 242 Million Yen in FY2020
June 24, 2021
- Daiichi Sankyo Chief Takes Home 170 Million Yen in FY2020: Securities Report
June 23, 2021
- Opdivo Expands Label for Combo Use with Avastin/Chemo in NSCLC
June 23, 2021
- Roche Diagnostics’ ALK CDx Ventana Approved for Alunbrig
June 23, 2021
- MSD Tops Foreign Pharma List in Japan in FY2020, but Big Players in a Melee
June 23, 2021
- FoundationOne OK’ed as a CDx for Opdivo/Keytruda’s MSI-High Use: Chugai
June 23, 2021
- Mochida Seeks Japan Approval of Once-Daily Epadel
June 23, 2021
- Nichi-Iko Halts Supplies of Some Edirol Generic Products, Re-Supply Expected for September
June 22, 2021
- Yoshindo Announces Shipment Curbs for Cymbalta Generics, 6 Other APIs
June 22, 2021
- Otsuka Group Takes the Lead to Launch Workplace Vaccination as Industry Peers Set to Follow
June 22, 2021
- NanoCarrier’s Angiosarcoma Med Bags US FDA’s Fast Track Designation
June 22, 2021
- Yoshindo’s Cymbalta Generics Out, but Supply Restrictions in Place: Sources
June 21, 2021
- Astellas CEO Earns 488 Million Yen in FY2020: Securities Filing
June 21, 2021
- Global Brands Clinch Targeted Sales despite COVID-19, Drive Japan Makers in FY2020
June 21, 2021
- Eisai Forms Strategic Alliance with BMS for Its First ADC
June 21, 2021
- Astellas to Write Off 21.5 Billion Yen as Peanut Allergy Vaccine Fails
June 18, 2021
- Merck’s COVID-19 Drug Candidate Enters PIII in Japan
June 18, 2021
- Zacras AG Now Available, Aloxi AG Expected for September Launch
June 18, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…